stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) EPS (diluted)
Zymeworks Inc.'s EPS (diluted) for fiscal 2025 was −$1.08, compared with −$1.62 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.02. Over the past ten years it has ranged from −$4.61 (fiscal 2021) to $1.90 (fiscal 2022); the current reading is higher than 73% of that period. Zymeworks Inc. ranks 318th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.08 | — |
| FY2024 | −$1.62 | — |
| FY2023 | −$1.72 | — |
| FY2022 | $1.90 | — |
| FY2021 | −$4.61 | — |
| FY2020 | −$3.58 | — |
| FY2019 | −$3.83 | — |
| FY2018 | −$1.26 | — |
| FY2017 | −$0.64 | — |
| FY2016 | −$2.65 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.62 | — |
| Mar 2026 | −$0.59 | — |
| Dec 2025 | −$0.55 | — |
| Sep 2025 | −$0.26 | — |
| 38 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| VCEL Vericel Corporation compare | $0.65 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| SEPN Septerna, Inc. compare | −$0.54 |
| ZYME Zymeworks Inc. | −$2.02 |
| IMNM Immunome, Inc. compare | −$2.53 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
| COAG Hemab Therapeutics Holdings, Inc. compare | −$53.87 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ZYME
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement